effective amount of the pharmaceutical composition comprising an antagonist which specifically binds to and inhibits the activity of said polypeptide.

40. (New) A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 18, the method comprising:

a) exposing a sample comprising a polypeptide of claim 18 to a compound, and

b) detecting agonist activity in the sample.

C1

41. (New) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 18, the method comprising:

a) exposing a sample comprising a polypeptide of claim 18 to a compound, and

b) detecting antagonist activity in the sample.

42. (New) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 21, the method comprising:

a) exposing a sample comprising the target polynucleotide to a compound, and

b) detecting altered expression of the target polynucleotide.

REMARKS

Claims 1, and 11-16 are pending in this divisional application. Claims 1, and 11-16 have been canceled by this amendment. Claims 18-42 have been added. No new matter is added by these amendments. Entry of these amendments is respectfully requested.

In the Restriction Requirement, the Examiner requested Applicants to elect one of the following inventions:

Group I (claims 1 and 11) drawn to polypeptides and a pharmaceutical composition.

Group II (claim 12) drawn to antibodies.

Group III (claim 13) drawn to antagonists.

Group IV (claim 14) drawn to methods for treating a developmental disorder by administering a pharmaceutical composition comprising cytokine/steroid receptor.

Group V (claims 15-16) drawn to methods for treating a disorder by administering an antagonist.

Applicants hereby elect, with traverse, to prosecute Group I, which includes claims 1 and 11 (the new equivalents of which are new claims 18, 19, 33, and 34), and drawn to polypeptides and pharmaceutical compositions. Applicants reserve the right to prosecute the subject matter of non-elected claims in subsequent divisional applications. Applicants traverse the restriction requirement because the invention encompassed by the claims of Groups I-V (drawn to polypeptides, antibodies to the polypeptides, modulators of the polypeptides, methods of use thereof) could be examined at the same time, without undue burden on the Examiner.

For example, a search of the prior art to determine the novelty of the antibodies (Group II) would substantially overlap with a search of the claims directed to the polypeptide (Group I). Similarly, a search of the prior art to determine the novelty of the polypeptides of the invention would provide information regarding the novelty of the modulators which bind to the polypeptides (Group III). Furthermore, the process claims of Groups IV and V, which depend from and are of the same scope as the product claims, should be rejoined and examined with the claims of Groups I and III. See the Commissioner's Notice in the Official Gazette of March 26, 1996, entitled: "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103 (b)", which sets forth the rules, upon allowance of the product claims, for rejoinder of the process claims covering the same scope of the products.

Accordingly, because the searches required to identify prior art relevant to the claims of Groups I-V would substantially overlap, Applicants respectfully submit that examination of all of the pending claims would pose no undue burden. Thus, Applicants request reconsideration and withdrawal of the Restriction Requirement and examination of the entirety of Applicants' claims.

Moreover, it is noted that the polynucleotides of original claim 2, expression vectors, host cells, methods of making the polypeptide encoded by the polynucleotides and methods of

hybridization have already been examined and issued in the parent application. Applicants submit herewith new claims 20-31, which are drawn to substantially the same invention as those claims, but of different scope. Applicants respectfully submit that there is minimal additional burden on the Examiner to examine those claims in addition to the claims elected in the present application, particularly in view of the searches and examination which were already conducted with respect to the previously issued claims, and the additional burden on Applicants to file, prosecute and maintain yet another application in this family. Thus, Applicants respectfully request that the Examiner consider examining these claims together in this application.

Applicants believe there is a claim fee due with this communication, as stated in the attached Transmittal Fee Sheet. Therefore, the Commissioner is hereby authorized to charge such fee to Deposit Account No. **09-0108.**

This form is enclosed in duplicate.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 4/18/00

Peng Ben Wang
Reg. No. 41,420
Direct Dial Telephone: (650) 621 -7574

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166